| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genes, BRCA1 | 120 | 2023 | 765 | 7.740 |
Why?
|
| Li-Fraumeni Syndrome | 35 | 2024 | 117 | 7.050 |
Why?
|
| Breast Neoplasms | 288 | 2024 | 20985 | 6.490 |
Why?
|
| Genes, BRCA2 | 89 | 2023 | 602 | 6.380 |
Why?
|
| BRCA2 Protein | 86 | 2024 | 799 | 6.200 |
Why?
|
| Germ-Line Mutation | 107 | 2024 | 1850 | 6.010 |
Why?
|
| BRCA1 Protein | 91 | 2024 | 1146 | 5.990 |
Why?
|
| Genetic Testing | 99 | 2024 | 3535 | 4.530 |
Why?
|
| Child of Impaired Parents | 24 | 2020 | 460 | 3.770 |
Why?
|
| Ovarian Neoplasms | 107 | 2023 | 4879 | 3.740 |
Why?
|
| Genetic Predisposition to Disease | 188 | 2024 | 17854 | 3.460 |
Why?
|
| Tumor Suppressor Protein p53 | 31 | 2024 | 2911 | 2.920 |
Why?
|
| Depression | 45 | 2024 | 8104 | 2.920 |
Why?
|
| Genetic Counseling | 46 | 2024 | 625 | 2.560 |
Why?
|
| Depressive Disorder | 28 | 2020 | 3728 | 2.540 |
Why?
|
| Mother-Child Relations | 17 | 2020 | 494 | 2.310 |
Why?
|
| Mothers | 29 | 2022 | 2191 | 2.010 |
Why?
|
| Mutation | 146 | 2024 | 30025 | 1.940 |
Why?
|
| Parent-Child Relations | 13 | 2023 | 760 | 1.800 |
Why?
|
| Stress, Psychological | 22 | 2017 | 4475 | 1.740 |
Why?
|
| Phthalazines | 9 | 2024 | 382 | 1.650 |
Why?
|
| Heterozygote | 62 | 2022 | 2798 | 1.650 |
Why?
|
| Cisplatin | 7 | 2020 | 1647 | 1.530 |
Why?
|
| Abdominal Pain | 28 | 2022 | 1069 | 1.510 |
Why?
|
| Maternal Behavior | 7 | 2020 | 307 | 1.480 |
Why?
|
| Adolescent Behavior | 8 | 2022 | 1186 | 1.470 |
Why?
|
| Female | 501 | 2024 | 391875 | 1.440 |
Why?
|
| Ovariectomy | 26 | 2022 | 614 | 1.430 |
Why?
|
| Parenting | 9 | 2023 | 698 | 1.340 |
Why?
|
| Depressive Disorder, Major | 17 | 2019 | 4760 | 1.300 |
Why?
|
| Tamoxifen | 11 | 2022 | 964 | 1.230 |
Why?
|
| Genes, p53 | 20 | 2019 | 712 | 1.210 |
Why?
|
| Humans | 593 | 2024 | 760437 | 1.210 |
Why?
|
| Parents | 19 | 2023 | 3563 | 1.180 |
Why?
|
| Saliva | 3 | 2021 | 827 | 1.170 |
Why?
|
| Receptor, erbB-2 | 17 | 2024 | 2553 | 1.160 |
Why?
|
| Affect | 5 | 2022 | 1483 | 1.120 |
Why?
|
| Adolescent | 138 | 2023 | 88196 | 1.070 |
Why?
|
| Hydrocortisone | 6 | 2015 | 1815 | 1.050 |
Why?
|
| Neoplasms | 45 | 2024 | 22083 | 1.040 |
Why?
|
| Jews | 13 | 2021 | 364 | 1.040 |
Why?
|
| Adult | 279 | 2024 | 220781 | 1.040 |
Why?
|
| Adaptation, Psychological | 15 | 2015 | 2629 | 1.020 |
Why?
|
| Mastectomy | 19 | 2024 | 1822 | 1.020 |
Why?
|
| Receptors, Estrogen | 19 | 2020 | 2204 | 0.990 |
Why?
|
| Child Behavior Disorders | 9 | 2016 | 804 | 0.970 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 2821 | 0.960 |
Why?
|
| Attitude | 4 | 2016 | 776 | 0.930 |
Why?
|
| DNA Repair | 12 | 2020 | 2044 | 0.910 |
Why?
|
| Internal-External Control | 11 | 2016 | 359 | 0.900 |
Why?
|
| Piperazines | 7 | 2024 | 2519 | 0.900 |
Why?
|
| Interpersonal Relations | 7 | 2018 | 1436 | 0.860 |
Why?
|
| Child | 119 | 2023 | 80086 | 0.850 |
Why?
|
| Middle Aged | 228 | 2024 | 220382 | 0.800 |
Why?
|
| Neoplastic Syndromes, Hereditary | 9 | 2022 | 245 | 0.790 |
Why?
|
| Germ Cells | 16 | 2024 | 634 | 0.780 |
Why?
|
| Receptors, Progesterone | 13 | 2021 | 1128 | 0.780 |
Why?
|
| Family | 23 | 2024 | 3189 | 0.750 |
Why?
|
| Risk Factors | 123 | 2024 | 74055 | 0.750 |
Why?
|
| Life Change Events | 11 | 2015 | 952 | 0.740 |
Why?
|
| Male | 213 | 2024 | 360035 | 0.740 |
Why?
|
| Penetrance | 9 | 2022 | 388 | 0.730 |
Why?
|
| Theory of Mind | 1 | 2022 | 91 | 0.710 |
Why?
|
| Genetics, Medical | 4 | 2019 | 336 | 0.700 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 14 | 2012 | 380 | 0.690 |
Why?
|
| Breast Neoplasms, Male | 14 | 2019 | 219 | 0.680 |
Why?
|
| Neoplasm Proteins | 31 | 2019 | 3610 | 0.680 |
Why?
|
| Irritable Mood | 2 | 2023 | 194 | 0.680 |
Why?
|
| Pedigree | 36 | 2021 | 4586 | 0.670 |
Why?
|
| Carcinoma, Ductal, Breast | 14 | 2020 | 1085 | 0.670 |
Why?
|
| Culture | 3 | 2016 | 623 | 0.650 |
Why?
|
| Medical History Taking | 7 | 2020 | 773 | 0.650 |
Why?
|
| DNA Mutational Analysis | 20 | 2015 | 4108 | 0.640 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 9 | 2024 | 926 | 0.640 |
Why?
|
| Child Abuse | 2 | 2019 | 1069 | 0.640 |
Why?
|
| Somatoform Disorders | 11 | 2013 | 423 | 0.630 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2020 | 549 | 0.630 |
Why?
|
| Mood Disorders | 3 | 2022 | 1127 | 0.620 |
Why?
|
| Genome-Wide Association Study | 21 | 2022 | 12653 | 0.620 |
Why?
|
| Young Adult | 64 | 2024 | 59068 | 0.610 |
Why?
|
| Precancerous Conditions | 10 | 2024 | 978 | 0.610 |
Why?
|
| Mammary Glands, Human | 7 | 2020 | 203 | 0.590 |
Why?
|
| Crime | 1 | 2019 | 202 | 0.590 |
Why?
|
| Risk Assessment | 48 | 2024 | 23953 | 0.590 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 2218 | 0.580 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2018 | 105 | 0.570 |
Why?
|
| Doxorubicin | 3 | 2020 | 2215 | 0.550 |
Why?
|
| Longitudinal Studies | 18 | 2022 | 14565 | 0.530 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2022 | 15867 | 0.520 |
Why?
|
| Thinking | 2 | 2018 | 320 | 0.520 |
Why?
|
| Attitude to Health | 11 | 2019 | 2025 | 0.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2019 | 3996 | 0.490 |
Why?
|
| Aged | 131 | 2024 | 168840 | 0.490 |
Why?
|
| Shame | 1 | 2015 | 80 | 0.480 |
Why?
|
| Community Networks | 1 | 2016 | 201 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2021 | 11729 | 0.480 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2018 | 192 | 0.480 |
Why?
|
| Antineoplastic Agents | 21 | 2024 | 13616 | 0.480 |
Why?
|
| Fathers | 4 | 2009 | 376 | 0.480 |
Why?
|
| Early Detection of Cancer | 9 | 2022 | 3183 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 10 | 2021 | 3631 | 0.470 |
Why?
|
| Neoplasms, Second Primary | 7 | 2010 | 1051 | 0.470 |
Why?
|
| Colorectal Neoplasms | 18 | 2022 | 6894 | 0.460 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2019 | 1517 | 0.460 |
Why?
|
| Psychotherapy | 4 | 2020 | 1646 | 0.450 |
Why?
|
| Carcinoma, Lobular | 8 | 2016 | 481 | 0.450 |
Why?
|
| Mental Disorders | 11 | 2022 | 6831 | 0.450 |
Why?
|
| Risk | 28 | 2020 | 9605 | 0.450 |
Why?
|
| Child Abuse, Sexual | 1 | 2016 | 397 | 0.450 |
Why?
|
| School Health Services | 2 | 2016 | 384 | 0.450 |
Why?
|
| Family Therapy | 3 | 2013 | 213 | 0.440 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 422 | 0.440 |
Why?
|
| Risk Reduction Behavior | 10 | 2018 | 1112 | 0.440 |
Why?
|
| Mass Screening | 12 | 2018 | 5424 | 0.440 |
Why?
|
| Gene Frequency | 13 | 2019 | 3637 | 0.440 |
Why?
|
| Neoplasms, Multiple Primary | 7 | 2021 | 590 | 0.440 |
Why?
|
| Neoplasm Staging | 24 | 2024 | 11096 | 0.440 |
Why?
|
| Mammography | 18 | 2024 | 2426 | 0.430 |
Why?
|
| Risk-Taking | 4 | 2012 | 1036 | 0.420 |
Why?
|
| Melanosis | 1 | 2014 | 93 | 0.420 |
Why?
|
| Truth Disclosure | 3 | 2011 | 433 | 0.410 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 162 | 0.410 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 934 | 0.410 |
Why?
|
| Anxiety | 9 | 2024 | 4558 | 0.410 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2024 | 132 | 0.410 |
Why?
|
| Psychiatric Status Rating Scales | 16 | 2014 | 6019 | 0.410 |
Why?
|
| Adolescent Development | 1 | 2016 | 282 | 0.410 |
Why?
|
| Lung Neoplasms | 9 | 2023 | 13312 | 0.400 |
Why?
|
| Personality Inventory | 8 | 2008 | 1019 | 0.400 |
Why?
|
| Factor V | 2 | 2010 | 167 | 0.400 |
Why?
|
| Father-Child Relations | 3 | 2016 | 48 | 0.400 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2014 | 616 | 0.400 |
Why?
|
| Pituitary-Adrenal System | 2 | 2012 | 549 | 0.390 |
Why?
|
| Premenopause | 5 | 2020 | 1039 | 0.390 |
Why?
|
| Complementary Therapies | 3 | 2006 | 486 | 0.390 |
Why?
|
| Breast | 10 | 2024 | 1962 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2014 | 727 | 0.390 |
Why?
|
| Psychotherapy, Group | 3 | 2013 | 412 | 0.390 |
Why?
|
| Aromatase Inhibitors | 5 | 2022 | 511 | 0.390 |
Why?
|
| Ethics, Professional | 2 | 2006 | 100 | 0.390 |
Why?
|
| Whole Body Imaging | 2 | 2017 | 281 | 0.380 |
Why?
|
| Tennessee | 5 | 2019 | 120 | 0.380 |
Why?
|
| Carcinoma | 7 | 2019 | 2328 | 0.380 |
Why?
|
| Personality Assessment | 8 | 2011 | 650 | 0.380 |
Why?
|
| Social Perception | 1 | 2015 | 433 | 0.380 |
Why?
|
| Resilience, Psychological | 2 | 2010 | 787 | 0.380 |
Why?
|
| Age of Onset | 24 | 2020 | 3302 | 0.380 |
Why?
|
| Phenotype | 19 | 2022 | 16585 | 0.370 |
Why?
|
| Anxiety Disorders | 5 | 2022 | 2717 | 0.370 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2012 | 698 | 0.370 |
Why?
|
| DNA-Binding Proteins | 17 | 2022 | 9598 | 0.370 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.360 |
Why?
|
| Loss of Heterozygosity | 10 | 2016 | 659 | 0.360 |
Why?
|
| Self Concept | 7 | 2019 | 1043 | 0.360 |
Why?
|
| Genetics, Population | 2 | 2015 | 939 | 0.360 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 58 | 0.350 |
Why?
|
| Gene Expression Profiling | 12 | 2019 | 9410 | 0.350 |
Why?
|
| Alleles | 18 | 2022 | 6908 | 0.350 |
Why?
|
| Ubiquitin-Protein Ligases | 7 | 2022 | 1889 | 0.350 |
Why?
|
| Prospective Studies | 43 | 2024 | 54339 | 0.350 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2018 | 1062 | 0.350 |
Why?
|
| Genes, APC | 2 | 2020 | 144 | 0.350 |
Why?
|
| Cyclohexanols | 1 | 2010 | 126 | 0.350 |
Why?
|
| Genetic Variation | 11 | 2021 | 6570 | 0.350 |
Why?
|
| Food Hypersensitivity | 1 | 2018 | 703 | 0.350 |
Why?
|
| Age Factors | 30 | 2021 | 18379 | 0.350 |
Why?
|
| Guilt | 2 | 2023 | 96 | 0.340 |
Why?
|
| Genotype | 24 | 2024 | 12976 | 0.340 |
Why?
|
| Health Promotion | 3 | 2018 | 2211 | 0.330 |
Why?
|
| Family Characteristics | 1 | 2014 | 1000 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 9 | 2022 | 2803 | 0.320 |
Why?
|
| Aged, 80 and over | 45 | 2024 | 58859 | 0.320 |
Why?
|
| Climacteric | 1 | 2008 | 57 | 0.320 |
Why?
|
| Keratins | 2 | 2010 | 497 | 0.320 |
Why?
|
| Transcription Factors | 25 | 2019 | 12121 | 0.310 |
Why?
|
| Models, Psychological | 5 | 2014 | 829 | 0.310 |
Why?
|
| Sex Characteristics | 3 | 2017 | 2633 | 0.310 |
Why?
|
| Carboplatin | 5 | 2021 | 793 | 0.310 |
Why?
|
| Prognosis | 36 | 2024 | 29551 | 0.310 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2021 | 3512 | 0.310 |
Why?
|
| Decision Making | 16 | 2015 | 3923 | 0.300 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 627 | 0.300 |
Why?
|
| Cystadenocarcinoma, Serous | 6 | 2016 | 478 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2017 | 8519 | 0.300 |
Why?
|
| Genetics | 2 | 2006 | 114 | 0.300 |
Why?
|
| Hot Flashes | 1 | 2010 | 330 | 0.290 |
Why?
|
| Prevalence | 21 | 2024 | 15698 | 0.290 |
Why?
|
| Personality Development | 3 | 2005 | 244 | 0.290 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 487 | 0.280 |
Why?
|
| Carcinoma in Situ | 3 | 2024 | 791 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2024 | 10180 | 0.280 |
Why?
|
| Recreation | 1 | 2007 | 125 | 0.270 |
Why?
|
| Fallopian Tube Neoplasms | 6 | 2010 | 328 | 0.270 |
Why?
|
| Genetic Association Studies | 7 | 2021 | 2723 | 0.270 |
Why?
|
| Databases as Topic | 1 | 2008 | 473 | 0.270 |
Why?
|
| Follow-Up Studies | 35 | 2020 | 39078 | 0.270 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 273 | 0.270 |
Why?
|
| Cohort Studies | 28 | 2024 | 41366 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2010 | 996 | 0.260 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2008 | 605 | 0.260 |
Why?
|
| Estrogen Receptor alpha | 3 | 2021 | 581 | 0.260 |
Why?
|
| DNA Damage | 8 | 2020 | 2441 | 0.260 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2024 | 276 | 0.260 |
Why?
|
| Multifactorial Inheritance | 3 | 2024 | 1378 | 0.260 |
Why?
|
| Population Surveillance | 6 | 2019 | 2603 | 0.260 |
Why?
|
| Salpingectomy | 2 | 2016 | 45 | 0.260 |
Why?
|
| Predictive Value of Tests | 17 | 2016 | 15257 | 0.260 |
Why?
|
| Adenomatous Polyposis Coli | 4 | 2020 | 218 | 0.260 |
Why?
|
| Executive Function | 1 | 2014 | 1383 | 0.250 |
Why?
|
| Telephone | 4 | 2021 | 626 | 0.250 |
Why?
|
| Psychometrics | 8 | 2019 | 3063 | 0.250 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 3246 | 0.250 |
Why?
|
| Sex Ratio | 1 | 2005 | 107 | 0.250 |
Why?
|
| Sexual Behavior | 3 | 2014 | 2178 | 0.250 |
Why?
|
| Achievement | 3 | 2011 | 289 | 0.240 |
Why?
|
| Hyperplasia | 5 | 2020 | 1153 | 0.240 |
Why?
|
| Allelic Imbalance | 3 | 2016 | 77 | 0.240 |
Why?
|
| Epigenomics | 1 | 2011 | 940 | 0.240 |
Why?
|
| Founder Effect | 2 | 2011 | 186 | 0.240 |
Why?
|
| Treatment Outcome | 30 | 2024 | 64591 | 0.240 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2018 | 427 | 0.240 |
Why?
|
| Confidentiality | 4 | 2006 | 609 | 0.240 |
Why?
|
| Prostatic Neoplasms | 11 | 2023 | 11095 | 0.240 |
Why?
|
| Medical Records | 4 | 2011 | 1407 | 0.240 |
Why?
|
| Interview, Psychological | 4 | 2013 | 809 | 0.240 |
Why?
|
| Retrospective Studies | 33 | 2024 | 80430 | 0.240 |
Why?
|
| Genetic Markers | 14 | 2011 | 2612 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 8 | 2024 | 5359 | 0.230 |
Why?
|
| Peer Group | 2 | 2008 | 684 | 0.230 |
Why?
|
| Social Adjustment | 5 | 2016 | 632 | 0.230 |
Why?
|
| Child Development | 1 | 2016 | 2302 | 0.230 |
Why?
|
| Personality | 2 | 2007 | 554 | 0.230 |
Why?
|
| Anticarcinogenic Agents | 3 | 2013 | 249 | 0.230 |
Why?
|
| Case-Control Studies | 32 | 2020 | 22097 | 0.220 |
Why?
|
| Quantitative Trait Loci | 7 | 2021 | 2104 | 0.220 |
Why?
|
| Mammaplasty | 5 | 2019 | 1239 | 0.220 |
Why?
|
| Ovary | 3 | 2008 | 958 | 0.220 |
Why?
|
| Community Health Services | 1 | 2008 | 656 | 0.220 |
Why?
|
| Neoplasm Metastasis | 9 | 2020 | 4903 | 0.220 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 5815 | 0.220 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 999 | 0.220 |
Why?
|
| Telomere | 3 | 2016 | 931 | 0.220 |
Why?
|
| Chromosome Mapping | 7 | 2020 | 4630 | 0.210 |
Why?
|
| Sex Factors | 8 | 2018 | 10538 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 9267 | 0.210 |
Why?
|
| Odds Ratio | 21 | 2018 | 9639 | 0.210 |
Why?
|
| Nuclear Proteins | 14 | 2015 | 5794 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2016 | 349 | 0.210 |
Why?
|
| Telomerase | 2 | 2021 | 745 | 0.210 |
Why?
|
| Body Height | 2 | 2019 | 1570 | 0.210 |
Why?
|
| Emotions | 4 | 2022 | 2735 | 0.210 |
Why?
|
| Statistics as Topic | 4 | 2018 | 2357 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 9 | 2017 | 4735 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 1177 | 0.200 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3710 | 0.200 |
Why?
|
| Comorbidity | 8 | 2022 | 10494 | 0.200 |
Why?
|
| Colonic Neoplasms | 5 | 2016 | 2529 | 0.200 |
Why?
|
| Databases, Genetic | 6 | 2018 | 1738 | 0.200 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2022 | 107 | 0.200 |
Why?
|
| Disclosure | 2 | 2006 | 748 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1089 | 0.200 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 11070 | 0.200 |
Why?
|
| Cognition | 7 | 2021 | 6973 | 0.190 |
Why?
|
| Haplotypes | 10 | 2023 | 2773 | 0.190 |
Why?
|
| Decision Support Techniques | 5 | 2013 | 1998 | 0.190 |
Why?
|
| Family Health | 9 | 2014 | 1257 | 0.190 |
Why?
|
| Mosaicism | 2 | 2022 | 475 | 0.190 |
Why?
|
| Sex Offenses | 2 | 2019 | 352 | 0.190 |
Why?
|
| Social Behavior | 2 | 2007 | 1132 | 0.190 |
Why?
|
| Health Education | 4 | 2016 | 1052 | 0.190 |
Why?
|
| Carrier Proteins | 11 | 2016 | 4936 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2016 | 373 | 0.190 |
Why?
|
| Mastectomy, Segmental | 5 | 2017 | 953 | 0.190 |
Why?
|
| Cadherins | 4 | 2013 | 904 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2006 | 732 | 0.190 |
Why?
|
| Social Environment | 5 | 2011 | 1020 | 0.190 |
Why?
|
| Sports | 1 | 2007 | 704 | 0.180 |
Why?
|
| Counseling | 4 | 2018 | 1545 | 0.180 |
Why?
|
| Attention | 4 | 2011 | 2391 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2002 | 4509 | 0.180 |
Why?
|
| Butylene Glycols | 1 | 2020 | 11 | 0.180 |
Why?
|
| United States | 28 | 2022 | 72202 | 0.180 |
Why?
|
| DNA Replication | 2 | 2020 | 1418 | 0.180 |
Why?
|
| Thyroid Neoplasms | 4 | 2022 | 2331 | 0.180 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2011 | 255 | 0.180 |
Why?
|
| Sick Role | 4 | 1998 | 230 | 0.180 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 1378 | 0.180 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2021 | 151 | 0.180 |
Why?
|
| Replication Protein A | 1 | 2020 | 52 | 0.180 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2020 | 40 | 0.180 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 2572 | 0.180 |
Why?
|
| Medication Errors | 1 | 2006 | 783 | 0.170 |
Why?
|
| Endometrial Neoplasms | 3 | 2023 | 1365 | 0.170 |
Why?
|
| Social Responsibility | 1 | 2002 | 386 | 0.170 |
Why?
|
| Religion | 1 | 2003 | 372 | 0.170 |
Why?
|
| Lignans | 1 | 2020 | 84 | 0.170 |
Why?
|
| Pain Measurement | 9 | 2021 | 3546 | 0.170 |
Why?
|
| Osteoprotegerin | 1 | 2020 | 176 | 0.170 |
Why?
|
| Social Support | 3 | 2008 | 2167 | 0.170 |
Why?
|
| Cancer Vaccines | 3 | 2023 | 1050 | 0.170 |
Why?
|
| Stomach Neoplasms | 5 | 2016 | 1428 | 0.170 |
Why?
|
| Fatigue | 2 | 2024 | 1550 | 0.160 |
Why?
|
| DNA Mismatch Repair | 3 | 2012 | 428 | 0.160 |
Why?
|
| Models, Molecular | 1 | 2009 | 5427 | 0.160 |
Why?
|
| DNA, Neoplasm | 6 | 2009 | 1745 | 0.160 |
Why?
|
| Medical Oncology | 6 | 2020 | 2318 | 0.160 |
Why?
|
| Southeastern United States | 1 | 2019 | 91 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2021 | 311 | 0.160 |
Why?
|
| Motivation | 5 | 2020 | 2006 | 0.160 |
Why?
|
| Survivors | 4 | 2015 | 2369 | 0.160 |
Why?
|
| Severity of Illness Index | 11 | 2018 | 15820 | 0.160 |
Why?
|
| Rad51 Recombinase | 4 | 2020 | 189 | 0.160 |
Why?
|
| Exons | 7 | 2016 | 2392 | 0.160 |
Why?
|
| Cell Lineage | 3 | 2020 | 2539 | 0.160 |
Why?
|
| Pain Perception | 2 | 2018 | 196 | 0.160 |
Why?
|
| Incidence | 20 | 2022 | 21322 | 0.160 |
Why?
|
| Genetic Loci | 4 | 2017 | 2626 | 0.160 |
Why?
|
| Puberty, Precocious | 1 | 2000 | 164 | 0.160 |
Why?
|
| Organs at Risk | 1 | 2020 | 359 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2016 | 3243 | 0.160 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2004 | 1208 | 0.160 |
Why?
|
| Pyridines | 1 | 2010 | 2868 | 0.150 |
Why?
|
| Quality of Life | 9 | 2024 | 13338 | 0.150 |
Why?
|
| Self-Assessment | 1 | 2000 | 396 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 3587 | 0.150 |
Why?
|
| Gynecomastia | 1 | 2019 | 87 | 0.150 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2023 | 555 | 0.150 |
Why?
|
| Primary Prevention | 5 | 2024 | 1186 | 0.150 |
Why?
|
| Patient Compliance | 3 | 2020 | 2689 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 10 | 2009 | 2895 | 0.150 |
Why?
|
| RecQ Helicases | 1 | 2018 | 53 | 0.150 |
Why?
|
| Marriage | 1 | 2000 | 351 | 0.150 |
Why?
|
| Consensus | 2 | 2018 | 3115 | 0.150 |
Why?
|
| Adult Children | 2 | 2022 | 103 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2009 | 1135 | 0.150 |
Why?
|
| Health Behavior | 5 | 2014 | 2637 | 0.150 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 3685 | 0.150 |
Why?
|
| Physicians | 3 | 2020 | 4586 | 0.150 |
Why?
|
| Intelligence | 1 | 2003 | 924 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 2 | 2019 | 532 | 0.150 |
Why?
|
| Recurrence | 12 | 2013 | 8466 | 0.150 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2018 | 103 | 0.150 |
Why?
|
| Platinum Compounds | 1 | 2018 | 94 | 0.150 |
Why?
|
| Bioethics | 2 | 1999 | 117 | 0.150 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 636 | 0.150 |
Why?
|
| American Cancer Society | 1 | 1997 | 69 | 0.150 |
Why?
|
| Time Factors | 17 | 2020 | 39947 | 0.140 |
Why?
|
| DNA Glycosylases | 2 | 2018 | 124 | 0.140 |
Why?
|
| Stem Cells | 3 | 2020 | 3522 | 0.140 |
Why?
|
| Bipolar Disorder | 2 | 2013 | 5089 | 0.140 |
Why?
|
| Child, Preschool | 17 | 2021 | 42209 | 0.140 |
Why?
|
| Internationality | 3 | 2019 | 1001 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2019 | 147 | 0.140 |
Why?
|
| Linkage Disequilibrium | 6 | 2021 | 2004 | 0.140 |
Why?
|
| Ethics, Medical | 2 | 2008 | 783 | 0.140 |
Why?
|
| Hamartoma Syndrome, Multiple | 3 | 2014 | 114 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 339 | 0.140 |
Why?
|
| MutS Homolog 2 Protein | 7 | 2009 | 197 | 0.140 |
Why?
|
| Pelvic Neoplasms | 2 | 2009 | 247 | 0.140 |
Why?
|
| Mutation, Missense | 6 | 2020 | 2571 | 0.140 |
Why?
|
| Parity | 5 | 2013 | 927 | 0.140 |
Why?
|
| Fallopian Tubes | 4 | 2010 | 177 | 0.140 |
Why?
|
| Sarcoma | 5 | 1999 | 1791 | 0.140 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 340 | 0.140 |
Why?
|
| Regression Analysis | 4 | 2019 | 6340 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2022 | 552 | 0.140 |
Why?
|
| Cluster Analysis | 5 | 2016 | 2711 | 0.130 |
Why?
|
| Carbolines | 1 | 2018 | 294 | 0.130 |
Why?
|
| Reproducibility of Results | 14 | 2018 | 20078 | 0.130 |
Why?
|
| Prenatal Diagnosis | 2 | 2015 | 1265 | 0.130 |
Why?
|
| Carcinogens | 1 | 2018 | 451 | 0.130 |
Why?
|
| Laboratories | 2 | 2016 | 462 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 3 | 2014 | 1197 | 0.130 |
Why?
|
| Problem Solving | 4 | 2011 | 441 | 0.130 |
Why?
|
| Models, Statistical | 5 | 2022 | 5078 | 0.130 |
Why?
|
| Chemoprevention | 2 | 2022 | 326 | 0.130 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2018 | 179 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 8 | 2020 | 7380 | 0.130 |
Why?
|
| Disease Susceptibility | 6 | 1998 | 1790 | 0.130 |
Why?
|
| Epidemiologic Methods | 2 | 2019 | 1336 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2000 | 552 | 0.130 |
Why?
|
| Intestine, Small | 1 | 2021 | 1205 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 1725 | 0.130 |
Why?
|
| Codon, Terminator | 1 | 2015 | 125 | 0.130 |
Why?
|
| Object Attachment | 2 | 2011 | 326 | 0.130 |
Why?
|
| Registries | 10 | 2016 | 8216 | 0.130 |
Why?
|
| Glucosides | 1 | 2020 | 512 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 642 | 0.120 |
Why?
|
| Histone Demethylases | 1 | 2018 | 320 | 0.120 |
Why?
|
| Genes, Mitochondrial | 1 | 2015 | 61 | 0.120 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2015 | 50 | 0.120 |
Why?
|
| Sleep | 3 | 2022 | 4760 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1987 | 2199 | 0.120 |
Why?
|
| Logistic Models | 11 | 2021 | 13240 | 0.120 |
Why?
|
| Chromosome Disorders | 2 | 2015 | 499 | 0.120 |
Why?
|
| Program Development | 3 | 2019 | 1297 | 0.120 |
Why?
|
| Survival Rate | 11 | 2021 | 12698 | 0.120 |
Why?
|
| Organizational Policy | 1 | 1997 | 432 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2016 | 410 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 430 | 0.120 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 269 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 4 | 2023 | 5491 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2021 | 623 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2020 | 621 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2016 | 535 | 0.120 |
Why?
|
| Pilot Projects | 8 | 2022 | 8611 | 0.120 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 7817 | 0.120 |
Why?
|
| Syndrome | 7 | 2022 | 3267 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 12 | 2010 | 6086 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2015 | 251 | 0.110 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1571 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 628 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2012 | 4569 | 0.110 |
Why?
|
| Organoids | 1 | 2020 | 741 | 0.110 |
Why?
|
| Anger | 1 | 1996 | 404 | 0.110 |
Why?
|
| Double-Blind Method | 8 | 2021 | 12320 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2018 | 1956 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2000 | 2502 | 0.110 |
Why?
|
| International Cooperation | 1 | 2020 | 1428 | 0.110 |
Why?
|
| Massachusetts | 5 | 2019 | 8826 | 0.110 |
Why?
|
| Kidney Neoplasms | 4 | 2021 | 4241 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2011 | 2318 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2014 | 170 | 0.110 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 7996 | 0.110 |
Why?
|
| Smoking | 6 | 2019 | 9046 | 0.110 |
Why?
|
| Androstadienes | 2 | 2012 | 348 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2019 | 1722 | 0.110 |
Why?
|
| Paclitaxel | 4 | 2018 | 1732 | 0.100 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2012 | 553 | 0.100 |
Why?
|
| Gene Duplication | 1 | 2014 | 314 | 0.100 |
Why?
|
| Survival Analysis | 8 | 2019 | 10075 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 329 | 0.100 |
Why?
|
| Chronic Disease | 12 | 2013 | 9309 | 0.100 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 16945 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 1667 | 0.100 |
Why?
|
| Infant | 12 | 2021 | 36183 | 0.100 |
Why?
|
| Fanconi Anemia | 1 | 2015 | 324 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 319 | 0.100 |
Why?
|
| Genes, Neoplasm | 2 | 2021 | 370 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5292 | 0.100 |
Why?
|
| Internet | 5 | 2021 | 3092 | 0.100 |
Why?
|
| Wilms Tumor | 2 | 1993 | 379 | 0.100 |
Why?
|
| Cell Cycle Proteins | 5 | 2016 | 3446 | 0.100 |
Why?
|
| Research Design | 6 | 2024 | 6168 | 0.100 |
Why?
|
| Connecticut | 2 | 2011 | 364 | 0.100 |
Why?
|
| Family Relations | 2 | 2008 | 317 | 0.100 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 26063 | 0.100 |
Why?
|
| Nuclear Family | 1 | 2013 | 311 | 0.100 |
Why?
|
| Disease Management | 3 | 2019 | 2501 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2011 | 64 | 0.100 |
Why?
|
| Aneuploidy | 1 | 2015 | 551 | 0.100 |
Why?
|
| Data Mining | 1 | 2016 | 551 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 561 | 0.100 |
Why?
|
| Epithelial Cells | 3 | 2019 | 3661 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2002 | 2975 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6475 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2013 | 3777 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 1996 | 418 | 0.100 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 1994 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 1494 | 0.100 |
Why?
|
| Tissue Array Analysis | 2 | 2012 | 550 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 1393 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2019 | 12932 | 0.090 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 29 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10759 | 0.090 |
Why?
|
| Polymorphism, Genetic | 7 | 2008 | 4287 | 0.090 |
Why?
|
| Intention | 1 | 2014 | 348 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 2821 | 0.090 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 908 | 0.090 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 916 | 0.090 |
Why?
|
| Placebos | 2 | 2018 | 1661 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2017 | 1784 | 0.090 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1990 | 44 | 0.090 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 186 | 0.090 |
Why?
|
| Genomics | 4 | 2020 | 5806 | 0.090 |
Why?
|
| Urban Population | 1 | 2019 | 2032 | 0.090 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2011 | 105 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1438 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 3 | 2019 | 97 | 0.090 |
Why?
|
| Information Dissemination | 2 | 2018 | 1127 | 0.090 |
Why?
|
| Amino Acid Substitution | 3 | 2016 | 1737 | 0.090 |
Why?
|
| Substance-Related Disorders | 7 | 2009 | 4416 | 0.090 |
Why?
|
| Psychological Theory | 1 | 2011 | 175 | 0.090 |
Why?
|
| Ki-67 Antigen | 3 | 2010 | 629 | 0.090 |
Why?
|
| Disease-Free Survival | 5 | 2021 | 6813 | 0.090 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 2073 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2020 | 1909 | 0.090 |
Why?
|
| Chromosome Aberrations | 3 | 2012 | 1771 | 0.090 |
Why?
|
| Nurses | 2 | 2020 | 2471 | 0.090 |
Why?
|
| Pregnancy | 13 | 2024 | 29831 | 0.090 |
Why?
|
| Angiomyolipoma | 1 | 2011 | 186 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 2204 | 0.090 |
Why?
|
| Diphosphonates | 3 | 2000 | 636 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2011 | 269 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 966 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 326 | 0.080 |
Why?
|
| Ambulatory Care | 3 | 2019 | 2771 | 0.080 |
Why?
|
| Research | 3 | 2012 | 1977 | 0.080 |
Why?
|
| DNA Methylation | 6 | 2013 | 4383 | 0.080 |
Why?
|
| Biomedical Research | 3 | 2019 | 3421 | 0.080 |
Why?
|
| Adenocarcinoma | 5 | 2017 | 6330 | 0.080 |
Why?
|
| Suicide, Attempted | 1 | 1998 | 1397 | 0.080 |
Why?
|
| Melanoma | 3 | 2022 | 5704 | 0.080 |
Why?
|
| Benzimidazoles | 3 | 2021 | 855 | 0.080 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 3344 | 0.080 |
Why?
|
| Simvastatin | 1 | 2011 | 346 | 0.080 |
Why?
|
| Telemedicine | 2 | 2024 | 3027 | 0.080 |
Why?
|
| Indoles | 2 | 2024 | 1833 | 0.080 |
Why?
|
| Signal Transduction | 8 | 2019 | 23397 | 0.080 |
Why?
|
| Minors | 2 | 2008 | 58 | 0.080 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2010 | 190 | 0.080 |
Why?
|
| Hysterectomy | 5 | 2016 | 857 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2020 | 181 | 0.080 |
Why?
|
| Ovarian Cysts | 1 | 2009 | 108 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2023 | 3220 | 0.080 |
Why?
|
| Demography | 4 | 2007 | 1648 | 0.080 |
Why?
|
| Sexual Partners | 1 | 2013 | 795 | 0.080 |
Why?
|
| Somatomedins | 1 | 2009 | 178 | 0.080 |
Why?
|
| Adnexa Uteri | 1 | 2008 | 40 | 0.080 |
Why?
|
| Gene Deletion | 2 | 2014 | 2667 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 1069 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2021 | 3405 | 0.080 |
Why?
|
| Observer Variation | 3 | 2006 | 2604 | 0.080 |
Why?
|
| Choroid Plexus | 1 | 1990 | 238 | 0.080 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5236 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 5778 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2017 | 36362 | 0.070 |
Why?
|
| Data Collection | 4 | 2020 | 3321 | 0.070 |
Why?
|
| Single Parent | 1 | 2007 | 32 | 0.070 |
Why?
|
| Point Mutation | 2 | 2015 | 1595 | 0.070 |
Why?
|
| Estrogens | 4 | 2020 | 1519 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 207 | 0.070 |
Why?
|
| Cholesterol | 1 | 2017 | 2902 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 3 | 2019 | 1376 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 1420 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 3190 | 0.070 |
Why?
|
| Breast Self-Examination | 3 | 2010 | 33 | 0.070 |
Why?
|
| Retinoblastoma | 2 | 2005 | 317 | 0.070 |
Why?
|
| Disease Progression | 6 | 2017 | 13484 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2012 | 1114 | 0.070 |
Why?
|
| Taxoids | 3 | 2017 | 666 | 0.070 |
Why?
|
| Protein Stability | 1 | 2009 | 577 | 0.070 |
Why?
|
| Genetic Research | 2 | 1999 | 171 | 0.070 |
Why?
|
| Incidental Findings | 3 | 2018 | 697 | 0.070 |
Why?
|
| Genetic Linkage | 5 | 1996 | 2382 | 0.070 |
Why?
|
| Students | 2 | 2016 | 1739 | 0.070 |
Why?
|
| Women's Health | 3 | 2007 | 2065 | 0.070 |
Why?
|
| Information Services | 1 | 2008 | 236 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2009 | 1118 | 0.070 |
Why?
|
| Vitamin D | 1 | 2021 | 3303 | 0.070 |
Why?
|
| Student Dropouts | 1 | 2007 | 27 | 0.070 |
Why?
|
| Suicide | 1 | 1998 | 1598 | 0.070 |
Why?
|
| Combined Modality Therapy | 9 | 2017 | 8522 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 5662 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1741 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2023 | 3796 | 0.070 |
Why?
|
| RNA, Small Interfering | 4 | 2020 | 3428 | 0.070 |
Why?
|
| Deafness | 1 | 2011 | 459 | 0.070 |
Why?
|
| Carcinoma, Large Cell | 1 | 2007 | 113 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2014 | 2683 | 0.070 |
Why?
|
| Reoperation | 1 | 2017 | 4300 | 0.070 |
Why?
|
| Menarche | 2 | 2010 | 532 | 0.070 |
Why?
|
| Awareness | 1 | 2011 | 647 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1989 | 339 | 0.070 |
Why?
|
| Pain, Intractable | 1 | 2007 | 132 | 0.070 |
Why?
|
| Europe | 5 | 2014 | 3419 | 0.070 |
Why?
|
| Psychotherapy, Brief | 1 | 2007 | 118 | 0.070 |
Why?
|
| Conduct Disorder | 1 | 2008 | 245 | 0.070 |
Why?
|
| Models, Biological | 3 | 2018 | 9462 | 0.070 |
Why?
|
| Abortion, Therapeutic | 1 | 2006 | 35 | 0.070 |
Why?
|
| DNA Repair Enzymes | 3 | 2009 | 346 | 0.070 |
Why?
|
| Fear | 1 | 2015 | 1471 | 0.070 |
Why?
|
| Narration | 1 | 2008 | 219 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 3 | 2018 | 999 | 0.070 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 1021 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 1337 | 0.070 |
Why?
|
| RNA, Messenger | 7 | 2022 | 12785 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2007 | 285 | 0.060 |
Why?
|
| Prothrombin | 1 | 2006 | 191 | 0.060 |
Why?
|
| Boston | 3 | 2005 | 9326 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3159 | 0.060 |
Why?
|
| Drug Design | 1 | 2011 | 1050 | 0.060 |
Why?
|
| Heart Rate | 1 | 2017 | 4190 | 0.060 |
Why?
|
| Arthritis | 1 | 2011 | 682 | 0.060 |
Why?
|
| Genetic Heterogeneity | 3 | 2007 | 733 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 4567 | 0.060 |
Why?
|
| DNA | 4 | 2015 | 7208 | 0.060 |
Why?
|
| Protein Folding | 1 | 2009 | 867 | 0.060 |
Why?
|
| Bone Resorption | 2 | 2000 | 723 | 0.060 |
Why?
|
| Alternative Splicing | 3 | 2013 | 1091 | 0.060 |
Why?
|
| Protein Binding | 3 | 2016 | 9340 | 0.060 |
Why?
|
| Psychotropic Drugs | 1 | 2011 | 888 | 0.060 |
Why?
|
| Sample Size | 2 | 2020 | 839 | 0.060 |
Why?
|
| Lung | 1 | 2023 | 9973 | 0.060 |
Why?
|
| Markov Chains | 3 | 2004 | 965 | 0.060 |
Why?
|
| Thyroxine | 2 | 1998 | 668 | 0.060 |
Why?
|
| Tumor Microenvironment | 4 | 2020 | 3874 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2005 | 231 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 2891 | 0.060 |
Why?
|
| Patient Care Planning | 2 | 2019 | 908 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2012 | 1944 | 0.060 |
Why?
|
| RNA Helicases | 2 | 2019 | 144 | 0.060 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 12429 | 0.060 |
Why?
|
| Nipples | 3 | 2009 | 229 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1533 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2007 | 2281 | 0.060 |
Why?
|
| Psychopathology | 3 | 2014 | 431 | 0.060 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 92 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 6128 | 0.060 |
Why?
|
| Self Report | 2 | 2015 | 3721 | 0.060 |
Why?
|
| Spain | 1 | 2005 | 489 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2009 | 1152 | 0.060 |
Why?
|
| Multivariate Analysis | 5 | 2010 | 12054 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 350 | 0.060 |
Why?
|
| Base Sequence | 10 | 2016 | 12449 | 0.060 |
Why?
|
| Analysis of Variance | 5 | 2011 | 6230 | 0.050 |
Why?
|
| Tuberous Sclerosis | 1 | 2011 | 1030 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2016 | 956 | 0.050 |
Why?
|
| Temperament | 2 | 2007 | 297 | 0.050 |
Why?
|
| Educational Status | 3 | 2003 | 2518 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2006 | 507 | 0.050 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 14661 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12969 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2020 | 1006 | 0.050 |
Why?
|
| Environment | 2 | 2006 | 1122 | 0.050 |
Why?
|
| Risk Management | 2 | 2004 | 557 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2008 | 2425 | 0.050 |
Why?
|
| T-Lymphocytes | 3 | 2017 | 10188 | 0.050 |
Why?
|
| Aggression | 1 | 2007 | 748 | 0.050 |
Why?
|
| Fungal Proteins | 2 | 1999 | 910 | 0.050 |
Why?
|
| Vaccines, Subunit | 1 | 2023 | 161 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2023 | 211 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2022 | 2326 | 0.050 |
Why?
|
| Communication | 3 | 2013 | 3868 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2006 | 483 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2018 | 8479 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2019 | 2468 | 0.050 |
Why?
|
| State Medicine | 1 | 2023 | 214 | 0.050 |
Why?
|
| Patient Preference | 1 | 2009 | 924 | 0.050 |
Why?
|
| Cell Proliferation | 5 | 2019 | 10425 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2020 | 26280 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2006 | 570 | 0.050 |
Why?
|
| Social Identification | 1 | 2002 | 108 | 0.050 |
Why?
|
| Trinucleotide Repeats | 2 | 2001 | 257 | 0.050 |
Why?
|
| Societies, Medical | 3 | 2018 | 3904 | 0.050 |
Why?
|
| Pain | 2 | 1996 | 5075 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 1154 | 0.050 |
Why?
|
| Protein Kinases | 3 | 2009 | 1607 | 0.050 |
Why?
|
| North America | 4 | 2010 | 1275 | 0.050 |
Why?
|
| Likelihood Functions | 2 | 2015 | 990 | 0.050 |
Why?
|
| Uncertainty | 2 | 2020 | 753 | 0.050 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2002 | 146 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 718 | 0.050 |
Why?
|
| Contraceptives, Oral | 2 | 2001 | 554 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 1409 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 2017 | 0.050 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2002 | 190 | 0.050 |
Why?
|
| Age Distribution | 4 | 2012 | 2878 | 0.050 |
Why?
|
| Genealogy and Heraldry | 1 | 2021 | 29 | 0.050 |
Why?
|
| Algorithms | 2 | 2014 | 14002 | 0.050 |
Why?
|
| Arylsulfotransferase | 1 | 2000 | 27 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 447 | 0.050 |
Why?
|
| Religion and Psychology | 1 | 2003 | 180 | 0.050 |
Why?
|
| International Agencies | 1 | 2021 | 243 | 0.050 |
Why?
|
| Sterilization, Tubal | 1 | 2001 | 75 | 0.050 |
Why?
|
| Health Personnel | 1 | 1995 | 3331 | 0.050 |
Why?
|
| Antidepressive Agents | 2 | 2011 | 2897 | 0.050 |
Why?
|
| Abortion, Spontaneous | 1 | 2006 | 533 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 316 | 0.050 |
Why?
|
| Radiotherapy | 3 | 2017 | 1498 | 0.050 |
Why?
|
| Nausea | 1 | 2024 | 679 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 4849 | 0.050 |
Why?
|
| Health Surveys | 2 | 2009 | 4056 | 0.050 |
Why?
|
| Immune System | 2 | 2016 | 794 | 0.050 |
Why?
|
| Ukraine | 1 | 2001 | 149 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2022 | 271 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 1165 | 0.040 |
Why?
|
| Flax | 1 | 2020 | 10 | 0.040 |
Why?
|
| Vomiting | 1 | 2024 | 652 | 0.040 |
Why?
|
| Social Desirability | 1 | 2000 | 46 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2012 | 2927 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6297 | 0.040 |
Why?
|
| Postal Service | 1 | 2020 | 96 | 0.040 |
Why?
|
| Estradiol | 2 | 2006 | 1935 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2006 | 1834 | 0.040 |
Why?
|
| Expressed Emotion | 2 | 2013 | 92 | 0.040 |
Why?
|
| Reproductive History | 1 | 2001 | 211 | 0.040 |
Why?
|
| Genome, Human | 2 | 2016 | 4423 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 2413 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 5143 | 0.040 |
Why?
|
| Alu Elements | 1 | 2000 | 115 | 0.040 |
Why?
|
| Philadelphia | 1 | 2020 | 266 | 0.040 |
Why?
|
| Speech | 1 | 2005 | 553 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 751 | 0.040 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.040 |
Why?
|
| Linear Models | 2 | 2010 | 5865 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2024 | 765 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2805 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 891 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 6525 | 0.040 |
Why?
|
| G2 Phase | 1 | 1999 | 136 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 2 | 2009 | 832 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 2008 | 0.040 |
Why?
|
| Preventive Health Services | 2 | 2019 | 567 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4789 | 0.040 |
Why?
|
| Adolescent Psychiatry | 1 | 2000 | 157 | 0.040 |
Why?
|
| Genetic Privacy | 1 | 1999 | 59 | 0.040 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2019 | 72 | 0.040 |
Why?
|
| Antigens, CD | 4 | 2013 | 4000 | 0.040 |
Why?
|
| Nitriles | 2 | 2017 | 969 | 0.040 |
Why?
|
| Sunscreening Agents | 1 | 2000 | 139 | 0.040 |
Why?
|
| Patient Satisfaction | 3 | 2015 | 3457 | 0.040 |
Why?
|
| Remission Induction | 3 | 2011 | 2394 | 0.040 |
Why?
|
| Informed Consent | 3 | 2007 | 1006 | 0.040 |
Why?
|
| Hydroxyurea | 1 | 2020 | 282 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2020 | 225 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5296 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2006 | 1051 | 0.040 |
Why?
|
| Patient Selection | 2 | 2009 | 4240 | 0.040 |
Why?
|
| Matched-Pair Analysis | 3 | 2006 | 283 | 0.040 |
Why?
|
| Absenteeism | 1 | 2000 | 247 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2000 | 504 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 1998 | 410 | 0.040 |
Why?
|
| Referral and Consultation | 3 | 2020 | 3596 | 0.040 |
Why?
|
| Paraproteins | 1 | 2018 | 38 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2215 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 2646 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2011 | 1988 | 0.040 |
Why?
|
| Life Expectancy | 3 | 2000 | 1240 | 0.040 |
Why?
|
| Cyclin D2 | 1 | 2018 | 98 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2023 | 5105 | 0.040 |
Why?
|
| Child Psychiatry | 1 | 2000 | 228 | 0.040 |
Why?
|
| Apoptosis | 3 | 2010 | 9468 | 0.040 |
Why?
|
| Frontal Lobe | 1 | 2004 | 1420 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2016 | 313 | 0.040 |
Why?
|
| Genetic Services | 1 | 1997 | 13 | 0.040 |
Why?
|
| Causality | 4 | 2016 | 1243 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 5421 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6471 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3486 | 0.040 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1997 | 58 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1703 | 0.040 |
Why?
|
| Mice | 8 | 2019 | 81402 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 4168 | 0.040 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 2413 | 0.040 |
Why?
|
| Research Subjects | 1 | 1999 | 249 | 0.040 |
Why?
|
| Animals | 12 | 2022 | 168253 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2008 | 2517 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 374 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2020 | 700 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 2020 | 1959 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 952 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 2 | 2017 | 2464 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 687 | 0.030 |
Why?
|
| Societies | 1 | 1997 | 108 | 0.030 |
Why?
|
| Carcinogens, Environmental | 1 | 1997 | 72 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1297 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1998 | 337 | 0.030 |
Why?
|
| Proctocolectomy, Restorative | 1 | 1998 | 190 | 0.030 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 4319 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2000 | 760 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2021 | 3445 | 0.030 |
Why?
|
| Molecular Sequence Data | 8 | 2001 | 17639 | 0.030 |
Why?
|
| Personality Tests | 2 | 1990 | 82 | 0.030 |
Why?
|
| Cyclophilins | 1 | 2016 | 47 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1998 | 412 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 119 | 0.030 |
Why?
|
| Colectomy | 2 | 1998 | 687 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1998 | 457 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 2012 | 1870 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1997 | 337 | 0.030 |
Why?
|
| tRNA Methyltransferases | 1 | 2016 | 52 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1988 | 2297 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2020 | 11526 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 621 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 790 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2004 | 1357 | 0.030 |
Why?
|
| Bone Density | 2 | 2000 | 3549 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2005 | 2858 | 0.030 |
Why?
|
| Defense Mechanisms | 1 | 1996 | 180 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 658 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 711 | 0.030 |
Why?
|
| Social Class | 1 | 2004 | 2003 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2000 | 1387 | 0.030 |
Why?
|
| Deltaretrovirus | 2 | 1986 | 162 | 0.030 |
Why?
|
| Biopsy | 2 | 2018 | 6765 | 0.030 |
Why?
|
| Insurance, Life | 1 | 1995 | 14 | 0.030 |
Why?
|
| Sequence Deletion | 3 | 2011 | 1494 | 0.030 |
Why?
|
| RNA, Satellite | 1 | 2014 | 17 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2020 | 907 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2019 | 783 | 0.030 |
Why?
|
| Canada | 2 | 2013 | 2119 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1997 | 423 | 0.030 |
Why?
|
| DNA Primers | 4 | 2007 | 2820 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 4575 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2020 | 851 | 0.030 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 331 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2020 | 8311 | 0.030 |
Why?
|
| Platinum | 1 | 2016 | 220 | 0.030 |
Why?
|
| DNA, Complementary | 3 | 2007 | 1992 | 0.030 |
Why?
|
| Postmenopause | 2 | 2016 | 2513 | 0.030 |
Why?
|
| Palliative Care | 1 | 1989 | 3585 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2018 | 599 | 0.030 |
Why?
|
| Sumoylation | 1 | 2015 | 83 | 0.030 |
Why?
|
| Collagen | 2 | 2000 | 2637 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 2205 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 422 | 0.030 |
Why?
|
| Professional Competence | 1 | 1997 | 431 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2011 | 6230 | 0.030 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2005 | 46 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2018 | 603 | 0.030 |
Why?
|
| Histidine | 2 | 2007 | 308 | 0.030 |
Why?
|
| Biological Products | 1 | 2003 | 911 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 2420 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 1385 | 0.030 |
Why?
|
| Reference Standards | 1 | 1997 | 1004 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2016 | 559 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2011 | 7029 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2014 | 191 | 0.030 |
Why?
|
| Gene Expression | 2 | 2016 | 7582 | 0.030 |
Why?
|
| Colonoscopy | 2 | 1998 | 1392 | 0.030 |
Why?
|
| Histones | 2 | 2018 | 2577 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 1999 | 873 | 0.030 |
Why?
|
| Centrosome | 1 | 2014 | 209 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 2912 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1887 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1998 | 784 | 0.030 |
Why?
|
| Social Isolation | 1 | 1996 | 364 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2005 | 3576 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3782 | 0.030 |
Why?
|
| Computational Biology | 2 | 2016 | 3510 | 0.030 |
Why?
|
| Menopause | 2 | 2019 | 1645 | 0.030 |
Why?
|
| Program Evaluation | 2 | 2015 | 2493 | 0.030 |
Why?
|
| Insurance, Health | 2 | 2015 | 2491 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7424 | 0.030 |
Why?
|
| Qualitative Research | 2 | 2014 | 3008 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 1999 | 1077 | 0.030 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 1997 | 497 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 4026 | 0.030 |
Why?
|
| Forecasting | 1 | 2002 | 2925 | 0.030 |
Why?
|
| Curriculum | 1 | 2006 | 3732 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 454 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2009 | 1647 | 0.030 |
Why?
|
| Teaching | 1 | 1980 | 1169 | 0.030 |
Why?
|
| Patient Participation | 1 | 2021 | 1442 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1183 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2014 | 18955 | 0.020 |
Why?
|
| Pandemics | 2 | 2022 | 8623 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2020 | 2929 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 1035 | 0.020 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2011 | 60 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1993 | 307 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 869 | 0.020 |
Why?
|
| Perception | 1 | 2018 | 1196 | 0.020 |
Why?
|
| Prejudice | 1 | 2015 | 571 | 0.020 |
Why?
|
| Triazoles | 1 | 2017 | 903 | 0.020 |
Why?
|
| Tubulin | 1 | 2015 | 692 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 714 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2013 | 4106 | 0.020 |
Why?
|
| Probability | 3 | 2002 | 2476 | 0.020 |
Why?
|
| Lysine | 1 | 2015 | 992 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 1997 | 1802 | 0.020 |
Why?
|
| Signal Detection, Psychological | 1 | 2011 | 84 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 1693 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2015 | 1528 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
| Peptides | 2 | 2000 | 4338 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 828 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 897 | 0.020 |
Why?
|
| Long-Term Care | 1 | 1995 | 633 | 0.020 |
Why?
|
| Vocabulary | 1 | 2011 | 165 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2010 | 127 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2016 | 961 | 0.020 |
Why?
|
| Evolution, Molecular | 2 | 2015 | 1891 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2006 | 4777 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2014 | 635 | 0.020 |
Why?
|
| Antibodies, Viral | 3 | 1987 | 3155 | 0.020 |
Why?
|
| Cytidine Deaminase | 1 | 2012 | 245 | 0.020 |
Why?
|
| Lod Score | 3 | 1995 | 602 | 0.020 |
Why?
|
| Cell Survival | 1 | 2020 | 5790 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1704 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3590 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 1841 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2019 | 2049 | 0.020 |
Why?
|
| HIV | 2 | 1987 | 1582 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 642 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2002 | 785 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1142 | 0.020 |
Why?
|
| Homosexuality | 2 | 1987 | 267 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 517 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 1075 | 0.020 |
Why?
|
| HIV Antibodies | 2 | 1987 | 1302 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2014 | 1633 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2021 | 4674 | 0.020 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2009 | 67 | 0.020 |
Why?
|
| Hormone Antagonists | 1 | 1989 | 107 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1363 | 0.020 |
Why?
|
| Child Behavior | 1 | 1995 | 847 | 0.020 |
Why?
|
| RNA Interference | 1 | 2018 | 2832 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 214 | 0.020 |
Why?
|
| Health Status | 1 | 2022 | 4071 | 0.020 |
Why?
|
| Women | 1 | 2011 | 223 | 0.020 |
Why?
|
| C-Reactive Protein | 2 | 2011 | 3822 | 0.020 |
Why?
|
| Leukemoid Reaction | 1 | 1988 | 18 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 793 | 0.020 |
Why?
|
| Catastrophization | 1 | 2012 | 348 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 1314 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3818 | 0.020 |
Why?
|
| Aging | 1 | 2007 | 8689 | 0.020 |
Why?
|
| Salpingostomy | 1 | 2008 | 8 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2852 | 0.020 |
Why?
|
| Oncogenes | 1 | 1994 | 1223 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1989 | 642 | 0.020 |
Why?
|
| Negativism | 1 | 2008 | 23 | 0.020 |
Why?
|
| Endodeoxyribonucleases | 1 | 2009 | 164 | 0.020 |
Why?
|
| Employment | 1 | 1995 | 1114 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 1604 | 0.020 |
Why?
|
| Judaism | 1 | 2008 | 32 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1987 | 1379 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15627 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 1990 | 412 | 0.020 |
Why?
|
| New York City | 2 | 1987 | 730 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 110 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3469 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1998 | 2566 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 102 | 0.020 |
Why?
|
| Paternal Behavior | 1 | 2007 | 33 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 882 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 748 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 107 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 1330 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 729 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 1990 | 479 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 2806 | 0.020 |
Why?
|
| Karyotyping | 2 | 2005 | 1171 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2012 | 802 | 0.020 |
Why?
|
| Ethics, Clinical | 1 | 2008 | 101 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2003 | 4649 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2008 | 156 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 3880 | 0.020 |
Why?
|
| Vinblastine | 1 | 2008 | 488 | 0.020 |
Why?
|
| Caregivers | 2 | 2011 | 2232 | 0.020 |
Why?
|
| Threonine | 1 | 2007 | 270 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2007 | 384 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 1974 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 2008 | 137 | 0.020 |
Why?
|
| Microdissection | 1 | 2007 | 151 | 0.020 |
Why?
|
| Schools | 1 | 1995 | 1488 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2009 | 276 | 0.020 |
Why?
|
| Cyclin E | 1 | 2007 | 156 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 1990 | 443 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 548 | 0.020 |
Why?
|
| San Francisco | 1 | 2006 | 162 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 732 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 457 | 0.020 |
Why?
|
| Collagen Type I | 2 | 2000 | 616 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2006 | 5866 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1923 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5764 | 0.020 |
Why?
|
| Agoraphobia | 1 | 2006 | 177 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2009 | 715 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5031 | 0.020 |
Why?
|
| Decision Trees | 1 | 2007 | 504 | 0.020 |
Why?
|
| Citalopram | 1 | 2008 | 402 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2008 | 360 | 0.020 |
Why?
|
| Self-Help Groups | 1 | 1987 | 189 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2860 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 489 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2009 | 5966 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 2048 | 0.020 |
Why?
|
| Imidazoles | 1 | 1991 | 1179 | 0.020 |
Why?
|
| Guanine | 1 | 2006 | 279 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 102 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 1610 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4277 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 5726 | 0.010 |
Why?
|
| Epidemiologic Research Design | 1 | 2008 | 368 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2015 | 1934 | 0.010 |
Why?
|
| Ossification, Heterotopic | 1 | 1987 | 235 | 0.010 |
Why?
|
| Ultrasonography, Mammary | 1 | 2006 | 238 | 0.010 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2006 | 306 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 13445 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 2005 | 292 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2006 | 395 | 0.010 |
Why?
|
| Israel | 1 | 2006 | 722 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2006 | 640 | 0.010 |
Why?
|
| Menstruation | 1 | 2005 | 307 | 0.010 |
Why?
|
| Mitochondria | 1 | 2017 | 3624 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1989 | 1597 | 0.010 |
Why?
|
| Epidemiology | 1 | 2006 | 279 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 336 | 0.010 |
Why?
|
| Iceland | 2 | 1995 | 184 | 0.010 |
Why?
|
| Tyrosine | 1 | 2007 | 1438 | 0.010 |
Why?
|
| Hand | 1 | 1988 | 902 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1998 | 2217 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 398 | 0.010 |
Why?
|
| Exercise | 1 | 2000 | 5874 | 0.010 |
Why?
|
| Authorship | 1 | 2006 | 283 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 931 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2008 | 671 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 412 | 0.010 |
Why?
|
| Homozygote | 1 | 2007 | 1794 | 0.010 |
Why?
|
| Cysts | 1 | 2008 | 681 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2013 | 5865 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 9176 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2008 | 968 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2007 | 1083 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2006 | 613 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1626 | 0.010 |
Why?
|
| Craniocerebral Trauma | 1 | 1987 | 490 | 0.010 |
Why?
|
| Physician's Role | 1 | 2008 | 916 | 0.010 |
Why?
|
| Retroviridae | 1 | 1984 | 850 | 0.010 |
Why?
|
| Diet | 1 | 2000 | 8058 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 2003 | 407 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2006 | 1086 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1987 | 1559 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5332 | 0.010 |
Why?
|
| Chromatin | 1 | 2013 | 2951 | 0.010 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 212 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7948 | 0.010 |
Why?
|
| Epithelium | 1 | 2005 | 1603 | 0.010 |
Why?
|
| Alkaline Phosphatase | 2 | 1998 | 866 | 0.010 |
Why?
|
| Mentors | 1 | 2006 | 660 | 0.010 |
Why?
|
| Adenine | 1 | 2006 | 986 | 0.010 |
Why?
|
| Lipids | 1 | 2011 | 3342 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1989 | 1588 | 0.010 |
Why?
|
| Mental Health | 1 | 2014 | 3241 | 0.010 |
Why?
|
| Cause of Death | 1 | 2010 | 3686 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2000 | 786 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 1432 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1994 | 2749 | 0.010 |
Why?
|
| Sequence Alignment | 2 | 1994 | 2180 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 22121 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2006 | 2253 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 1545 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 1347 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 1254 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2008 | 2242 | 0.010 |
Why?
|
| Peptide Chain Termination, Translational | 1 | 1998 | 29 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1998 | 184 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2898 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2000 | 2687 | 0.010 |
Why?
|
| G1 Phase | 1 | 1999 | 403 | 0.010 |
Why?
|
| Life Style | 3 | 1997 | 3909 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1988 | 2907 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2000 | 392 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1999 | 359 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 1999 | 299 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1987 | 2300 | 0.010 |
Why?
|
| Osteocalcin | 1 | 1998 | 274 | 0.010 |
Why?
|
| Ethics Committees, Research | 1 | 1999 | 196 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 150 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1986 | 2610 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 2047 | 0.010 |
Why?
|
| Gingival Hyperplasia | 1 | 1997 | 19 | 0.010 |
Why?
|
| CpG Islands | 1 | 2002 | 1225 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 2819 | 0.010 |
Why?
|
| Federal Government | 1 | 1999 | 267 | 0.010 |
Why?
|
| Impulsive Behavior | 1 | 1980 | 346 | 0.010 |
Why?
|
| Privacy | 1 | 1999 | 233 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2000 | 404 | 0.010 |
Why?
|
| Cyclins | 1 | 1999 | 594 | 0.010 |
Why?
|
| Arginine | 1 | 2000 | 933 | 0.010 |
Why?
|
| Receptors, Parathyroid Hormone | 1 | 1997 | 332 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 374 | 0.010 |
Why?
|
| Osteolysis | 1 | 1998 | 275 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1988 | 2525 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 678 | 0.010 |
Why?
|
| Ileum | 1 | 1998 | 557 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 783 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1996 | 192 | 0.010 |
Why?
|
| Multigene Family | 1 | 1999 | 1077 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1997 | 231 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2007 | 2035 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2000 | 1526 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2001 | 1509 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1998 | 983 | 0.010 |
Why?
|
| Government Regulation | 1 | 1999 | 524 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 330 | 0.010 |
Why?
|
| CA-125 Antigen | 1 | 1997 | 280 | 0.010 |
Why?
|
| Body Fluids | 1 | 1996 | 319 | 0.010 |
Why?
|
| Common Bile Duct | 1 | 1954 | 106 | 0.010 |
Why?
|
| Rectum | 1 | 1998 | 892 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2000 | 1185 | 0.010 |
Why?
|
| Creatinine | 1 | 1998 | 1898 | 0.010 |
Why?
|
| Dogs | 1 | 1997 | 3839 | 0.010 |
Why?
|
| Ethical Review | 1 | 1992 | 27 | 0.010 |
Why?
|
| Bile Ducts | 1 | 1954 | 282 | 0.010 |
Why?
|
| Amino Acids | 1 | 1998 | 1717 | 0.010 |
Why?
|
| Pediatrics | 1 | 2007 | 3593 | 0.010 |
Why?
|
| Fasting | 1 | 1998 | 1600 | 0.010 |
Why?
|
| Parental Consent | 1 | 1992 | 63 | 0.010 |
Why?
|
| Fadrozole | 1 | 1991 | 3 | 0.010 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 1991 | 21 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4461 | 0.010 |
Why?
|
| Hydroxyprogesterones | 1 | 1991 | 24 | 0.010 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1980 | 1073 | 0.010 |
Why?
|
| Androstenedione | 1 | 1991 | 131 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 5776 | 0.010 |
Why?
|
| Hypochondriasis | 1 | 1991 | 93 | 0.010 |
Why?
|
| Norway | 1 | 1992 | 497 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2003 | 2016 | 0.010 |
Why?
|
| Duodenum | 1 | 1954 | 489 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 4921 | 0.010 |
Why?
|
| Estrone | 1 | 1991 | 234 | 0.010 |
Why?
|
| Codon | 1 | 1992 | 602 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2000 | 1807 | 0.010 |
Why?
|
| Netherlands | 1 | 1995 | 2218 | 0.010 |
Why?
|
| Health Services | 1 | 1995 | 752 | 0.010 |
Why?
|
| Genes | 1 | 1993 | 1844 | 0.010 |
Why?
|
| Comprehensive Health Care | 1 | 1990 | 123 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1991 | 616 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1993 | 915 | 0.000 |
Why?
|
| Gender Identity | 1 | 1994 | 765 | 0.000 |
Why?
|
| Autoimmune Diseases | 1 | 1980 | 2247 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 4174 | 0.000 |
Why?
|
| Gastrointestinal Tract | 1 | 1954 | 831 | 0.000 |
Why?
|
| Etidronic Acid | 1 | 1987 | 63 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18216 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1997 | 8163 | 0.000 |
Why?
|
| Aldosterone | 1 | 1991 | 866 | 0.000 |
Why?
|
| Acute Disease | 1 | 1997 | 7230 | 0.000 |
Why?
|
| Phosphorus | 1 | 1987 | 336 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 7597 | 0.000 |
Why?
|
| Rats | 2 | 1997 | 23712 | 0.000 |
Why?
|
| Kinetics | 1 | 1991 | 6377 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 11900 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 9003 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1980 | 1371 | 0.000 |
Why?
|
| Aspirin | 1 | 1987 | 3134 | 0.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1980 | 1373 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1980 | 2123 | 0.000 |
Why?
|